Key result
Expected rise in Asian HF burden demands improved data, trial representation, and therapy implementation.
Why the study?
Heart failure burden is expected to rise in Asia due to an aging population and increasing non-communicable diseases, despite treatment advances.
This review highlights the growing burden of heart failure in Asia and emphasizes the need for improved treatment utilization, better representation in clinical trials, and expanded training for healthcare providers.
Calls for enhanced HF infrastructure in Asia; leaves open whether better trial representation will improve regional outcomes.
Heart failure (HF) is a significant global health concern, particularly in Asia, where over half of the world's population resides. Despite advances in treatment, the burden of HF is expected to rise in the region due to the aging population and an increase in non-communicable diseases associated with HF risk. This narrative review examines the current state of HF in Asia, highlighting differences in treatment utilization, underrepresentation of Asian individuals in clinical trials, emerging therapies, and implementation strategies, including the potential use of polypills and the need for expanded HF training opportunities for healthcare providers.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2024) conducted a review in Heart failure. The burden of heart failure is expected to rise in Asia, highlighting the need for improved data collection, increased representation in clinical trials, and better implementation of therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: